君实生物,反转在即

抗体圈
28 Apr

最近,国内创新药领域捷报频传。既有在商业化层面即将迎来明确的盈利节点,让创新药不在仅仅是“烧钱游戏”;也有进一步在BD上斩获deal,让此前“一过性”的License收益能成为持续;更有一些新品在临床数据不断超越国际标准,带领中国创新药走向世界前沿……而在这一批本土创新势力中,随着各家一季度财报的披露,君实生物作为曾经的创新药龙头,吃到过PD-1这类重磅产品的红利,谈过大额deal,也在国际化的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10